|
Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms
|
Jul 2019
|
Surgical Pathology Clinic
|
myelodysplastic syndromes (MDS)
|
|
Defeating anaemia in myelodysplastic syndromes: another step forward
|
Sep 2017
|
Lancet Oncol
|
myelodysplastic syndromes (MDS)
|
|
Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria
|
Sep 2014
|
J Clin Invest
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Decreased plasma cytokines associate with low platelet counts in aplastic anemia and immune thrombocytopenic purpura
|
Apr 2012
|
J Thromb Haemost
|
|
|
Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate
|
Jan 2017
|
Expert Rev Hematol
|
myelodysplastic syndromes (MDS)
|
|
Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study
|
Oct 2023
|
Leukemia
|
aplastic anemia
|
|
Deacetylase Inhibitors for the Treatment of Myelodysplastic Syndromes
|
Jul 2014
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes
|
Jan 2021
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
|
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
|
Oct 2020
|
Haematologica
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Cytogenetics in benzene-associated myelodysplastic syndromes and acute myeloid leukemia: new insights into a disease continuum
|
Mar 2014
|
Ann N Y Acad Sci
|
myelodysplastic syndromes (MDS)
|
